ClinicalTrials.gg
RecruitingNCT06427304ARNOLDUpdated Apr 20, 2026

Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure

An observational study in Cardiac Amyloidosis, sponsored by Gérond'if. Recruiting at 36 sites in France. Open to participants aged 80 Years and older. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Gérond'if · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
637
Ages
80 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Amyloid Neuropathies, Familial with a site in France — 15 open to participants now, 16 under way, 1 of them phase 3. Amyloid Neuropathies, Familial · France.

Planned enrollment
4th of 12
637 · median 175
Started
2024
with 3 others
Observational
12 of 35
9 open now
Primary completion
2027-07
later than 9 of 15 live
Registered
30th of 35
by date

Among the 35 studies in Amyloid Neuropathies, Familial with a site in France, this one is the 4th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2024, is one of 12 observational ones, reaches primary completion later than 9 of the 15 other live ones, and was the 30th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

15 of the 35 studies in Amyloid Neuropathies, Familial with a site in France are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 80 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Amyloid Neuropathies, Familial with a site in France, or all of them as a file.
02

Study summary

Tne aim purpose of this observational, multicentre and propective study is to determine the prevalence of cardiac amyloidosis in geriatric patients aged 80 years and older hospitalized within the last 12 months for heart failure with left ventricular hypertrophy (septum ≥ 12 mm) on echocardiography

Read the detailed description

Patients recruitment will be curry out in 31 geriatric or cardiologic centres.

Patients will be recruited for 24 months. Each patient will participate in the study for 12 months (baseline visit, follow-up phone calls every 3 months up to 12 months i.e., at 3, 6, 9 and 12 months).

The following data will be collected at teh baseline visit: Medical history, demography, clinical data, frailty status assessed by Fried, Triage Risk Screening Tool (TRST), triggers for cardiac decompensation, biological examination, genetic testing, echocardiographic data and other data.

Bone scanning with 99mTc-DPD or 99mTc-HMDP (early or late time with SPECT will be done during hospitalization or after discharge depending on availability at the imaging centre.

The results of each examination will be evaluated to establish the existence and degree of fixation in the myocardium and to determine its distribution.

Follow-up phone s will be conducted every 3 months up to 12 months to collect hospitalizations for heart failure, hospitalizations for other cardio-vascular events, hospitalizations for non-cardiac events, admission to nursing homes or long-term care (LTC) facilities and death

03

Conditions studied

  • Cardiac Amyloidosis

Keywords

  • Cardiac amyloidosis
  • Heart failure with left ventricular hypertrophy
  • Positive bone scintigraphy
04

Who can participate

Ages eligible
80 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with cardiac amyloidosis expressed by a positive bone scintigraphy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 80 years
  • Hospitalised for decompensation of heart failure in the last 12 months
  • Subjects with hypertrophy of the septum or left ventricle at cardiac echography (defined as ≥ 12 mm)
  • Subjects able to undergo a bone scintigraphy scan
  • Subjects willing to participate

Exclusion criteria

Exclusion Criteria:

  • Subjects refusing to participate
  • Subjects admitted to palliative care unit.
  • Subjects under guardianship
  • Subjects with a definite diagnosis of cardiac amyloidosis
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
637 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Assessment of the number of patients with cardiac amyloidosis according bon scintigraphy

    Time frame: At inclusion

Secondary outcomes

  1. Assessment of commorbidity risk according Charlson Comorbidity Index (CCI)

    The Charlson Comorbidity Index (CCI) assesses the level of comorbidity by considering the level of severity of 19 predefined comorbid disorders and the number of disorders present among them.

    Time frame: At inclusion

  2. Assessment of the degree of patient dependence according Katz Index of Independence in Activities of Daily Living (ADL)

    Katz Index of Independence in Activities of Daily Living is an unabbreviated scale title. This Index ranks adequacy of performance in the six functions of bathing, dressing, toileting, transferring, continence, and feeding. Patients are scored yes/no for independence in each of the six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment.

    Time frame: At inclusion

  3. Measuring cognitive impairment according Mini-Mental State Examination (MMSE) score

    The Mini-Mental State Examination is an unabbreviated scale title. This scale was developed as a brief screening tool to provide a quantitative evaluation of cognitive impairment and to record cognitive changes over time. The measure yields a total score of 30. A score of 23 or less is the generally accepted cutoff point indicating the presence of cognitive impairment. Levels of impairment have also been classified as none (24-30); mild (18-23) and severe (0-17)

    Time frame: At inclusion

  4. Estimating the probability of neuropathic pain according "DN4 Questionnaire"

    This questionnaire is an unabbreviated score title, it was originally developed and validated in French (4 items of neuropathic pain). It was identified as one of the most suitable neuropathic pain screening tools for clinical use: * Sensitivity: Ranges from 75-98%. Proven high sensitivity for central neuropathic pain and polyneuropathies. Sensitivity is low for tigeminal neuralgia. Moderate sensitivity for detecting a neuropathic component of pain in people with chronic pain. * Specificity: Ranges from 37-96%.

    Time frame: At inclusion

  5. Assessment of physical frailty according Fried scale

    This is an unabbreviated scale title. Assessment of 5 dimensions: * 0, 1 or 2 pathological dimensions = lack of frailty * 3, 4 or 5 pathological dimensions = presence of frailty

    Time frame: At inclusion

  6. Assessment of Failty status using the Short Emergency Geriatric Assessment (SEGA)

    This is an unabbreviated scale title. * if SEGA score \< ou = 8 : Not very frail * if it contained in the interval \[9;11\] : Rather frail * if it \> ou = 12 : Very frail

    Time frame: At inclusion

07

Study locations

35 of 36 sites recruiting
  • Geriatric Department, Broca Hospital
    Paris, IIe-de-France 75013, France
    Recruiting
  • CHU Nantes
    Nantes, Loire-Atlantique 44000, France
    Recruiting
    • Anne Sophie BOUREAU, MD · Contact
  • CHU Poitiers
    Poitiers, New Aquitaine 86000, France
    Recruiting
    • Marc PACCALIN, MD, PHD · Contact
  • CHU Rouen, Charles Nicole hospital
    Rouen, Normandy 76000, France
    Recruiting
    • Frédéric ROCA, MD · Contact
  • CHU Montpellier
    Montpellier, Occitanie 34090, France
    Recruiting
    • Hubert BLAIN, MD, PHD · Contact
  • CHU Toulouse
    Toulouse, Occitanie 31300, France
    Recruiting
    • Olivier TOULZA, MD · Contact
  • CHU Amiens Picardie
    Amiens, 80000, France
    Recruiting
    • Nysrine BENNOUNA, MD · Contact
  • CHU Angers
    Angers, 49100, France
    Recruiting
    • Cédric NNWEILER, MD, PHD · Contact
  • CHU Bordeaux
    Bordeaux, 33000, France
    Recruiting
    • Isabelle BOURDEL-MARCHASSON, MD, PHD · Contact
  • Centre Hospitalier de Carcassonne
    Carcassonne, 11100, France
    Recruiting
    • Hanna BAKANOVA, Dr · Contact
  • Centre Hospitalier Intercommunal de Castres-Mazamet
    Castres, 81100, France
    Recruiting
    • Soumiya MENHOUR, MD · Contact
  • CHU Trousseau-Tours
    Chambray-lès-Tours, 37170, France
    Recruiting
    • Laurent FAUCHIER, MD, PHD · Contact
  • CHU Dijon
    Dijon, 21000, France
    Recruiting
    • Jérémie VOVELLE, MD · Contact
  • CHU Grenoble Alpes
    Grenoble, 38700, France
    Recruiting
    • Laure ALLAN-PATTOGLIA, MD · Contact
  • CHU Lille
    Lille, 59000, France
    Recruiting
    • François PUISIEUX, MD, PHD · Contact
  • CHU Limoges
    Limoges, 87000, France
    Recruiting
    • Achille TCHALLA, MD · Contact
  • CHU Lyon
    Lyon, 69002, France
    Recruiting
    • Michel CHUZEVILLE, MD · Contact
  • CHU Marseille
    Marseille, 13005, France
    Recruiting
    • Anne-Laure COUDERC, MD, PHD · Contact
  • Clinique du Millénaire-Montpellier
    Montpellier, 34000, France
    Recruiting
    • Philippe GALLET DE SANTERRE, Dr · Contact
  • CHRU Nancy
    Nancy, 54000, France
    Recruiting
    • Laure JOLY, MD · Contact
  • CHU Nice
    Nice, 06000, France
    Recruiting
    • Olivier GUERIN, MD, PHD · Contact
  • Hôpital Privé Gériatrique LES SOURCES-Nice
    Nice, 06100, France
    Recruiting
    • Anne-Marie BARISIC, MD · Contact
  • CHU Orléans
    Orléans, 45100, France
    Recruiting
    • Matthieu COULONGEAT, MD · Contact
  • CHU Rennes
    Rennes, 35000, France
    Recruiting
    • Dominique SOMME, MD, PHD · Contact
    • Erwan DONAL, MD, PhD · Contact
  • CHRU Tours-Bretonneau Hospital
    Tours, 37000, France
    Recruiting
    • Bertrand FOUGERE, MD, PHD · Contact
  • Clinique Saint Joseph Trelaze
    Trélazé, 49800, France
    Recruiting
    • Laureen LABORY, MD · Contact
  • Médipôle Hôpital Mutualiste Villeurbanne
    Villeurbanne, 69100, France
    Recruiting
    • Antoine JOBBE-DUVAL, MD · Contact
  • Ambroise Paré Hospital
    Boulogne-Billancourt, Île-de-France Region 92100, France
    Recruiting
    • Marion PEPIN, MD · Contact
  • Corentin Celton Hospital
    Issy-les-Moulineaux, Île-de-France Region 92130, France
    Not yet recruiting
    • Anthony MEZIERE, MD · Contact
  • Charles Foix Hospital
    Ivry-sur-Seine, Île-de-France Region 94200, France
    Recruiting
    • Joël BELMIN, MD, PHD · Contact
  • Emile Roux Hospital
    Limeil-Brévannes, Île-de-France Region 94450, France
    Recruiting
    • Amaury BROUSSIER, MD · Contact
  • GH Sud Ile-de-France
    Melun, Île-de-France Region 77000, France
    Recruiting
    • Cyrus MOÏNI, MD · Contact
  • Lariboisière Hospital
    Paris, Île-de-France Region 75010, France
    Recruiting
    • Matthieu LILAMAND, MD · Contact
  • Saint Joseph Hospital
    Paris, Île-de-France Region 75014, France
    Recruiting
    • Yara ANTAKLY HANON, MD · Contact
  • Europeen Georges Pompidou Hospital
    Paris, Île-de-France Region 75015, France
    Recruiting
    • Elena PAILLAUD, MD, PHD · Contact
  • Bretonneau Hospital
    Paris, Île-de-France Region 75018, France
    Recruiting
    • Virginie FOSSEY-DIAZ, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2027, 36 months after the start.

Of 74 observational studies under Amyloid Neuropathies, Familial, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 120. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2024
First posted
May 23, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Jul 2, 2027
CompletionEst.
Feb 2, 2028
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06427304
Lead sponsor
Gérond'if
Responsible party
Sponsor
First posted
May 23, 2024
Start date
Jul 1, 2024
Primary completion
Jul 2, 2027 (estimated)
Completion
Feb 2, 2028 (estimated)
Last update
Apr 20, 2026

Study contacts

Isabelle Dufour
Contact
isabelle.dufour@gerondif.org
+33 (0) 185781011
Prisca Lucas, MPH PhD
Contact
prisca.lucas@gerondif.org
+33 (0)185737323
Olivier Hanon, MD PhD
study chair · Geriatric Department, Broca hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion